MINOCIN
LOE ApproachingNDAORALCAPSULE
Approved
May 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MINOCIN by Bausch + Lomb is clinical pharmacology following a single dose of minocin 200 mg administered intravenously to 10 healthy male subjects, serum concentrations of minocycline ranged from 2. Approved for infections caused by the following gram-negative bacteria, infections caused by the following gram-positive bacteria, the treatment of the following infections due to susceptible isolates of the designated bacteria: rocky mountain spotted fever and 5 more indications. First approved in 1990.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MINOCIN is a minocycline-based tetracycline antibiotic administered orally as capsules, used to treat infections caused by susceptible Gram-positive and Gram-negative bacteria, as well as rickettsial infections including Rocky Mountain spotted fever. The drug works by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit, exerting bacteriostatic activity. MINOCIN has a serum elimination half-life of 15–23 hours and is suitable for flexible dosing regimens (100 mg every 12 hours or 200 mg once daily).
LOE Approaching
MINOCIN is approaching loss of exclusivity with moderate competitive pressure (30/100) and brand team focus likely shifting toward lifecycle management and cost containment strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Following a single dose of Minocin 200 mg administered intravenously to 10 healthy male subjects, serum concentrations of minocycline ranged from 2.52 to 6.63 mcg/mL (average 4.18 mcg/mL) at the end of infusion and 0.82 to 2.64 mcg/mL (average 1.38 mcg/mL) after 12 hours. In a…
Worked on MINOCIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.